RecruitingHepatocellular CarcinomaRadiation Exposure
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.
Sponsor: University of Tennessee
You may qualify if…
- ✓ All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study
- ✓ Must be able to schedule and tolerate additional PET/CT imaging following therapy
- ✓ Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.
You may not qualify if…
- ✕ Patients that are not candidates for Y90 radioembolization therapy
- ✕ Patients that cannot tolerate additional imaging procedures following therapy
- ✕ Patients that cannot tolerate the additional blood draws required for this study
- ✕ Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study
Where it's recruiting
Tennessee
Knoxville
Source: ClinicalTrials.gov · NCT03686709 · last updated 2018-09-27